THE SINGLE BEST STRATEGY TO USE FOR BREAST CANCER

A further bispecific, humanized IgG1 antibody that is definitely less than investigation is zenocutuzumab (MCLA-128), which acts through two unbiased mechanisms of action: inhibition of HER2–HER3 signalling and elimination of tumour cells by means of ADCC. MCLA-128 functions by using a ‘dock and block’ mechanism whereby 1 arm on the antibody